Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-8539 in Overactive Bladder
NCT00876421Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of ONO-8539 in overactive bladder (OAB) (5 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Overactive bladder symptoms at 12 weeks. Started Apr 2009; status: completed.
02
Drugs
ONO-8539
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00876421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00876421.